ChinaBio Partnering Forum 2026: APAC Biotech Deals Recap

Key Takeaways

• ChinaBio Partnering Forum 2026 focuses on cross-border biotech/pharma partnering in China.
• The event takes place in-person (Shanghai) and virtually.
• Attendees include pharma/biotech leaders, investors, and researchers.

The ChinaBio Partnering Forum 2026, scheduled for April 28–29 (in-person, Shanghai) and May 6–7 (virtual), aims to facilitate networking and deal-making within China's dynamic life sciences ecosystem. This event brings together biotech and pharmaceutical leaders, investors, and researchers to explore opportunities for drug development, commercialization, and strategic partnerships.

Post-event update (June 06, 2026): ChinaBio® Partnering Forum 2026 has ended after concluding on April 29, 2026. This preview has been refreshed with post-conference context; see related coverage and the event hub for readouts and regulatory takeaways.

As the largest life science partnering event in China, the ChinaBio Partnering Forum serves as a crucial platform for cross-border collaborations. The 2026 forum continues this tradition, offering both in-person and virtual participation options to maximize global engagement. With a focus on novel technologies and innovative therapies, the event is a key meeting point for companies seeking to expand their presence in the Chinese market and forge alliances with local partners.

Event Overview

The ChinaBio Partnering Forum 2026 will be held from April 28–29, 2026, at the Kerry Hotel Pudong in Shanghai, China, followed by a virtual partnering extension on May 6–7, 2026. The forum is designed to foster networking and collaboration in drug development, commercialization, and partnerships within China's life sciences sector.

IntelligenceRegulatory Impact▾

NMPA, PMDA, and TGA are the agencies to watch. Regulatory relevance reads medium for biotech. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Co-located Events

The ChinaBio Partnering Forum 2026 will be co-located with:

• Cell & Gene Therapy Summit at ChinaBio: April 28–30, 2026, Shanghai. This summit is expected to gather over 1200 global leaders, focusing on partnerships, R&D, investment, technology, and regulations in the cell and gene therapy space.
• Antibody & ADC Summit.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Potential Participants

Companies expected to participate include Cereno Scientific, Servier, and Cymab. Lei Fang from Excalipoint Therapeutics, with a focus on oncology, is listed as a speaker.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for biotech pricing, access, and launch sequencing.

Deals Landscape

While specific data readouts and clinical milestones directly tied to the ChinaBio Partnering Forum 2026 are not available, recent deals involving AbbVie and Chinese partners highlight the ongoing trends in partnering within the region. These deals, though not directly linked to the 2026 forum, illustrate the types of collaborations that the event aims to foster.

Recent deals include:

• AbbVie's partnership with Haisco Pharmaceutical Group for a portfolio of pain compounds, granting AbbVie rights outside Greater China. The deal involves development, manufacturing, and commercialization, with a potential value of up to $745 million.
• AbbVie's collaboration with RemeGen for RC148, a PD-1/VEGF bispecific antibody, granting AbbVie rights outside Greater China. This deal includes $650 million upfront and up to $4.95 billion in milestones.
• AbbVie's agreement with Zejing Biopharmaceutical for Alveltamig, a DLL3-targeting trispecific T-cell engager, granting AbbVie global rights. The deal includes $100 million upfront and up to $1.07 billion in total.

IntelligenceStrategic Takeaways▾

ChinaBio Partnering Forum 2026 focuses on cross-border biotech /pharma partnering in China. The event takes place in-person (Shanghai) and virtually. Attendees include pharma/biotech leaders, investors, and researchers.

Market & Investor Implications

The ChinaBio Partnering Forum 2026 provides a platform for companies to explore potential collaborations and investments in the Chinese biotech market. While specific financial impacts and investment trends directly resulting from the 2026 forum are yet to be seen, the event's focus on cross-border partnerships and innovative technologies suggests opportunities for growth and expansion in the region.

IntelligenceEvidence Quality▾

Claims are grounded in the cited primary and secondary sources, with editorial review applied before publication.

What to Watch Next

As the ChinaBio Partnering Forum 2026 approaches, keep an eye on announcements regarding key presentations, speakers, and participating companies. Monitoring the deals and partnerships that emerge from the forum will provide insights into the evolving landscape of the Chinese biotech industry.

Frequently Asked Questions

• What is the primary focus of the ChinaBio Partnering Forum 2026?

  The forum focuses on facilitating cross-border biotech and pharmaceutical partnerships, with an emphasis on drug development and commercialization in China.

• Where and when will the event take place?

  The in-person event will be held on April 28–29, 2026, at the Kerry Hotel Pudong in Shanghai, China, followed by a virtual partnering extension on May 6–7, 2026.

• Who are the expected participants?

  Participants include biotech and pharmaceutical leaders, investors, and researchers from around the world.

• Are there any co-located events?

  Yes, the forum will be co-located with the Cell & Gene Therapy Summit at ChinaBio and the Antibody & ADC Summit.

• What kind of deals are expected to emerge from the forum?

  The forum aims to foster deals related to drug development, commercialization, and strategic partnerships in the Chinese biotech market, similar to recent deals involving AbbVie and Chinese partners.

References

1. Venture Valuation
2. FirstWord Pharma
3. Shimadzu Scientific Instruments
4. Essex Bio-Technology
5. Catalan Life Sciences
6. BioProcess International
7. Informa Connect
8. Cision
9. Servier
10. Biotech Canada

Related coverage

• Clinical Trials Outsourcing Market Size: 2026-2034 Growth Outlook
• Hengrui Pharma and Kailera Therapeutics Present Ribupatide Data at ADA 2026
• NMPA China FDA Drug Approval: 2026 Pathways, Timelines & Impact